Osteoarthritis (OA) Musculoskeletal Diseases
Conditions
Interventions
This study is a prospective observational clinical study designed to evaluate the safety, feasibility, and clinical effectiveness of ultrasound-guided intra-articular injection of polyacrylamide hydro
Sponsors
University Hospital Southampton NHS Foundation Trust
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Adults aged 18 years or over 2. Diagnosis of symptomatic synovial joint pathology considered suitable for intra-articular injection by the treating clinician. 3. Clinical and/or radiological evidence of joint disease affecting the target joint 4. Persistent symptoms despite standard conservative management, including pharmacological and/or non-pharmacological treatment where appropriate 5. Ability to understand the study requirements and provide written informed consent 6. Willingness and ability to comply with study procedures and follow-up assessments
Exclusion criteria
Exclusion criteria: 1. Age under 18 years 2. Active local infection at the injection site or systemic infection 3. Previous intra-articular injection to the target joint within the preceding 6 months 4. Previous surgery to the target joint within the preceding 6 months or planned surgery during the study period 5. Known hypersensitivity or contraindication to the study intervention, local anaesthetic, or antibiotic prophylaxis 6. Known coagulopathy or current anticoagulant therapy where injection is contraindicated 7. Diagnosis of inflammatory arthropathy (e.g., rheumatoid arthritis) or other systemic inflammatory joint disease affecting the target joint 8. Pregnancy or breastfeeding 9. Inability to complete study procedures or follow-up assessments 10. Any medical, psychological, or social condition which, in the opinion of the investigator, would make participation unsuitable or place the participant at undue risk 11. Only participants with capacity to provide informed consent will be included 12. Individuals lacking capacity to consent will not be recruited
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Knee outcome measured using Oxford Knee Score at baseline, 6 months, 12 months and 24 months;Foot & Ankle outcome measured using Manchester-Oxford Score MOX-FQ at baseline, 6 months, 12 months and 24 months;Shoulder outcome measured using Oxford Shoulder Score at baseline, 6 months, 12 months and 24 months;Wrist outcome measured using DASH score at baseline, 6 months, 12 months and 24 months;Pain measured using visual analogue scale at baseline, 6 months, 12 months and 24 months;Quality of life measured using EQ5D at baseline, 6 months, 12 months and 24 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Prevalence of complications & adverse events measured using patient notes at annual check up to two years follow-up following recruitment to the study;Requirement for additional treatments, including repeat injections or surgical intervention during the follow up period measured using patient notes at annual check up to two years follow-up following recruitment to the study | — |
Countries
England, Scotland, United Kingdom, Wales
Contacts
Public ContactNiall Hill
Outcome results
None listed